SOURCE-LINKED STUDY SUMMARY
0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial.
Full paper summarizedQuality not appraised
- What was studied
- A randomized, double-masked phase 3 trial tested topical thymosin beta-4 formulation RGN-259 for persistent corneal epithelial defects.
- Who / model studied
- Eighteen adults with stage 2 or 3 neurotrophic keratopathy completed the study: 10 active and 8 placebo.
- Studied dose & schedule
- Participants applied 0.1% RGN-259 ophthalmic solution or vehicle placebo five times daily for four weeks.
- What the study found
- At four weeks, complete healing occurred in 6/10 active versus 1/8 placebo eyes, but the primary comparison missed significance (p=0.0656).
- Limitations & context
- Recruitment stopped early at 18 rather than 46 participants. The local eye result cannot establish systemic tendon or muscle healing; one treatment-related adverse event occurred.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.3390/ijms24010554